Advertisement

Canagliflozin

You have accessRestricted Access
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria
Meg Jardine, Zien Zhou, Hiddo J. Lambers Heerspink, Carinna Hockham, Qiang Li, Rajiv Agarwal, George L. Bakris, Christopher P. Cannon, David M. Charytan, Tom Greene, Adeera Levin, Jing-Wei Li, Brendon L. Neuen, Bruce Neal, Richard Oh, Megumi Oshima, Carol Pollock, David C. Wheeler, Dick de Zeeuw, Hong Zhang, Bernard Zinman, Kenneth W. Mahaffey and Vlado Perkovic

CJASN February 2021, CJN.15260920; DOI: https://doi.org/10.2215/CJN.15260920

Add to Selected Citations
You have accessRestricted Access
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m²
George Bakris, Megumi Oshima, Kenneth W. Mahaffey, Rajiv Agarwal, Christopher P. Cannon, George Capuano, David M. Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Hiddo J.L. Heerspink, Adeera Levin, Bruce Neal, Richard Oh, Carol Pollock, Norman Rosenthal, David C. Wheeler, Hong Zhang, Bernard Zinman, Meg J. Jardine and Vlado Perkovic

CJASN December 2020, 15 (12) 1705-1714; DOI: https://doi.org/10.2215/CJN.10140620

Add to Selected Citations
Open Access
How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?
Joshua J. Neumiller and Rita R. Kalyani

CJASN November 2019, 14 (11) 1667-1669; DOI: https://doi.org/10.2215/CJN.05340419

Add to Selected Citations